Stock Events

Stock Events

Renalytix

€0

0

+€0+0% Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

18MarExpected

Q4 2024

-0.01

0.32

0.65

0.99

Expected EPS

-0.01370745

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2O90.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Bio-Rad Laboratories

Bio-Rad Laboratories offers a range of products for the clinical diagnostics market, competing in the same space as Renalytix's kidney diagnostic solutions.

Quest Diagnostics

Quest Diagnostics provides diagnostic testing, information, and services, including for kidney function, directly competing with Renalytix's offerings.

Laboratory Corporation of America Holdings operates in the same clinical laboratory services sector, offering tests that overlap with Renalytix's kidney health diagnostics.

Exact Sciences Corp focuses on the detection of cancer, but its expansion into broader diagnostic solutions presents competition for Renalytix's diagnostic tests.

Guardant Health

Guardant Health operates in the precision oncology field but competes with Renalytix through its development of diagnostics that could overlap with kidney disease detection.

Fulgent Genetics

Fulgent Genetics provides comprehensive genetic testing, directly competing in the genetic markers space for diseases, including those related to the kidney.

QuidelOrtho Corporation is a provider of diagnostic testing solutions that compete with Renalytix by offering tests that can be used in diagnosing kidney conditions.

NeoGenomics specializes in cancer diagnostics and testing services but competes with Renalytix by offering tests that could be relevant for kidney disease patients.

Thermo Fisher Scientific

Thermo Fisher Scientific offers a wide range of healthcare solutions, including diagnostics that compete with Renalytix's kidney disease diagnostic products.

About

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company's products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. It has a license agreement with Mount Sinai Health System to develop and commercialize its products in connection with the application of artificial intelligence for the diagnosis of kidney disease. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. The company was incorporated in 2018 and is based in London, the United Kingdom.

Show more...

CEO

Mr. James R. McCullough M.B.A.

Employees

46

Country

United Kingdom

ISIN

US75973T2006

Listings

0 Comments

Share your thoughts

FAQ

What is Renalytix stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Renalytix stocks are traded under the ticker 2O90.MU.

When is the next Renalytix earnings date?▼

Renalytix is going to release the next earnings report on November 03, 2026.

How many employees does Renalytix have?▼

As of April 14, 2026, the company has 46 employees.

In which sector is Renalytix located?▼

Renalytix operates in the Health & Wellness sector.

When did Renalytix complete a stock split?▼

Renalytix has not had any recent stock splits.

Where is Renalytix headquartered?▼

Renalytix is headquartered in London, United Kingdom.